Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of TPI-120 With On-Body Injector vs Fylnetra in Healthy Subjects
NCT06918587Phase 1Completed
- Sponsor
- Kashiv BioSciences
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pegfilgrastim in febrile neutropenia (FN) (2 arms), sponsored by Kashiv BioSciences. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Curve from Time Zero to Last Quantifiable Concentration and 1 more. Started Sep 2024; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT06918587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06918587.